Australia's competition regulator opposes Australian Clinical Labs' offer to buy Healius
Dec 15 (Reuters) - Australia's competition regulator said on Friday it had decided to oppose the proposed acquisition of Healius Limited HLS.AX by Australian Clinical Labs. ACL.AX (Reporting by Archishma Iyer in Bengaluru; Editing by Shinjini Ganguli) ((Archishma.Iyer@thomsonreuters.com;))
Recent news on Healius
See all newsAustralia's Healius rises on sale of unit Agilex; Jefferies lifts PT
Brief: Healius To Sell Agilex Biolabs To Novotech
Australia's Healius rises on sale of unit Agilex Biolabs to Novotech Health
Brief: Healius Requests Trading Halt
Brief: Healius Expects To Achieve T27 Target Of Mid-To-High Single-Digit EBIT Margins By Dec 2028